DNA-based Test for Colorectal Cancer Now Available

PreGen-26™, a DNA-based test for colorectal cancer, is now available for use by physicians and patients, according to Laboratory Corporation of America Holdings.

The test, based on EXACT Sciences Corporation's genomics-based technology, targets hereditary non-polyposis colorectal cancer (HNPCC), an inherited predisposition to develop colorectal cancer. People with this syndrome have an 80 percent lifetime risk of developing colorectal cancer.

PreGen-26 is intended to detect the presence of colorectal cancer, not predict the disease. In active colorectal cancer, DNA from tumors is shed into the colon and carried out of the body. The LabCorp test is a non-invasive method for patients to collect whole stool samples in the privacy of their home.

The sample is then analyzed by LabCorp using EXACT Sciences' genomics-based technology to isolate and analyze the DNA shed from colorectal tumors.

Other Sources: Laboratory Corporation of America